Cipla announced that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at its Goa manufacturing facility from 16-27 September 2019.
The inspection ended with 12 observations, none of which are related to data integrity. The Company will respond to the agency within the stipulated timeline.